Back to top

Stoke Therapeutics reinstated with an Overweight at JPMorgan

JPMorgan analyst Jessica Fye reinstated coverage of Stoke Therapeutics (STOK) with an Overweight rating and $40 price target The firm sees a high p...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Stoke Therapeutics, Inc. (STOK)